**To:** Doa, Maria[Doa.Maria@epa.gov]; Cleland-Hamnett, Wendy[Cleland-Hamnett.Wendy@epa.gov]; Flattery, Priscilla[Flattery.Priscilla@epa.gov]
**From:** Henry, Tala
**Sent:** Tue 2/18/2014 6:42:21 PM
**Subject:** Fw: Meeting with Hill staff on CDR and WV.

Below is what was provided to Priscilla on the Monday after first press; I do not know that this is the version provided to the press.

The events as they occurred:

# Ex. 5 - Deliberative

**From:** Henry, Tala
**Sent:** Monday, January 13, 2014 12:12 PM
**To:** Flattery, Priscilla
**Subject:** RE: checking on WV chem

EPA has not identified having received the Eastman study referenced in the press or any other test data for 4-methylcyclohexanemethanol under requirements of TSCA (e.g., Section 8(e)) nor through voluntary programs (e.g. HPV Challenge).

The toxicity value cited in the press and on the Eastman MSDS is for acute toxicity (oral and dermal tests are both provided in the MSDA). The LD50 value (865 mg/kg) is such EPA would generally characterize the chemical as having moderate acute toxicity by both routes of exposure. Because the acute toxicity cited is not what EPA considers "extreme" or "high" toxicity in EPA's guidance for TSCA 8(e) reporting http://www.epa.gov/opptintr/tsca8e/pubs/1991guidance.pdf), reporting the study to EPA is not triggered under TSCA Section 8(e).

Other Info:

The chemical cited in the press is a commercial mixture containing potentially 6 other constituent chemicals. It is not clear from the Eastman MSDS what chemical(s), the commercial product or constituents, were tested, but presumably it would be the commercial product, as this is the subject of the MSDS.

Tala R. Henry, Ph.D.

Director, Risk Assessment Division

Office of Pollution Prevention and Toxics

U.S. Environmental Protection Agency

T: 202-564-2959

E: henry.tala@epa.gov

**From:** Flattery, Priscilla
**Sent:** Monday, January 13, 2014 11:20 AM
**To:** Henry, Tala
**Subject:** checking on WV chem

Did we find anything

Priscilla Flattery

Chief of Staff, OPPT

202-564-2718